A phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-Naive, High Grade Non-Muscle Invasive Bladder Cancer.

Investigator: Raj Satkunasivam, MD

Study Coordinator: Cinthya Yesenia Obando Perez

Status: Enrolling

ClinicalTrials.gov Number: NCT03091660

Phone: 346.238.6123

Protocol Number: Pro00021110

Description

This randomized phase III trial studies Tokyo-172 strain bacillus Calmette-Guerin (BCG) solution with or without a vaccination using Tokyo-172 strain BCG to see how well it works compared with TICE BCG solution in treating patients with bladder cancer that has not spread to muscle. BCG is a non-infectious bacteria that when instilled into the bladder may stimulate the immune system to fight bladder cancer. Giving different versions of BCG with vaccine therapy may prevent bladder cancer from returning. NCT03091660
More to Explore
Live Chat Available